SELLAS Life Sciences Group Stock Jumps 9.5%

Shares of the biotech company rise after positive analyst commentary

Apr. 6, 2026 at 4:38pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavy industrial biotech machinery and equipment, conveying the technical and complex nature of pharmaceutical research and development without any text or identifiable elements.The rise in SELLAS Life Sciences Group's stock price reflects investor interest in the company's cancer immunotherapy pipeline, though the path forward remains uncertain.Waltham Today

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) jumped 9.5% on Monday, trading as high as $4.46 per share. The stock closed at $4.52, with approximately 1.4 million shares traded, down from the average daily volume of 8.4 million shares.

Why it matters

SELLAS is a clinical-stage biotech company focused on developing cancer immunotherapies targeting the Wilms' tumor 1 (WT1) antigen. The stock's rise comes after positive analyst commentary, indicating potential investor interest in the company's pipeline and future prospects.

The details

Several equity analysts have recently weighed in on SELLAS shares. Weiss Ratings reaffirmed a 'sell (d-)' rating, while Maxim Group increased its price target from $7 to $10 and maintained a 'buy' rating. Overall, the stock has a 'hold' consensus rating and a $10 average price target.

  • SELLAS shares closed at $4.13 on the previous trading day.
  • The stock has a 50-day moving average of $4.53 and a 200-day moving average of $3.10.

The players

SELLAS Life Sciences Group, Inc.

A clinical-stage biopharmaceutical company focused on developing cancer immunotherapies targeting the Wilms' tumor 1 (WT1) antigen.

Weiss Ratings

An equity research firm that reaffirmed a 'sell (d-)' rating on SELLAS shares.

Maxim Group

An equity research firm that increased its price target on SELLAS shares from $7 to $10 and maintained a 'buy' rating.

Got photos? Submit your photos here. ›

The takeaway

The jump in SELLAS Life Sciences Group's stock price suggests potential investor interest in the company's cancer immunotherapy pipeline, particularly its lead candidate galinpepimut-S (GPS). However, the mixed analyst commentary indicates the stock may continue to see volatility as the company progresses its clinical development efforts.